First author [ref.] | Main conclusion | SIGN grade | Study type | Exposure/ occupation | Subjects n |
Merget [10] | No relationship (NSBHR) | 2- | Cohort study | Platinum salts | 275 |
Tarlo [11] | + (NSBHR, FEV1, FVC) | 3 | Descriptive study of register | Isocyanates | 235 |
Cote [12] | + (SIC), no relationship (FEV1, FVC, NSBHR) | 2+ | Longitudinal | Plicatic acid (Western red cedar) | 48 |
Sorgdrager [13] | + (FEV1) | 2- | Longitudinal | Fluorides | 122 |
Pisati [14] | No relationship (FEV1, VC, NSBHR) | 2- | Longitudinal | TDI | 25 |
Perfetti [15] | + (NSBHR, FEV1) | 2- | Longitudinal | Various HMW and LMW agents | 99 |
Park [16] | + (NSBHR) | 2- | Longitudinal | TDI | 35 |
Chang-Yeung [17] | + (NSBHR, FEV1,FVC) | 2- | Longitudinal | Western red cedar | 125 |
Maghni [8] | + (NSBHR) | 2+ | Longitudinal | Various HMW and LMW agents | 133 |
Lozewicz [18] | + (NSBHR, FEV1) | 2+ | Longitudinal | Isocyanates (TDI, MDI) | 56 |
Hudson [19] | + (FEV1) | 2- | Longitudinal | Crab; various HMW and LMW agents | 63 |
Malo [20] | + (NSBHR, FEV1) | 2+ | Longitudinal | Various HMW and LMW agents | 80 |
Park [21] | + (NSBHR) | 2- | Longitudinal | TDI | 41 |
Mapp [22] | + (SIC), no relationship (FEV1, NSBHR) | 2- | Longitudinal | TDI | 35 |
Labreque [23] | + (NSBHR, FEV1) | 2- | Longitudinal | Isocyanates | 79 |
Padoan [9] | + (NSBHR, FEV1) | 2++ | Longitudinal | TDI | 87 |
Soyseth [24] | - (Higher NSBHR at baseline favours good prognosis), no relationship (FEV1) | 2+ | Longitudinal | Fluorides | 38 |
Moscato [25] | + (FEV1) | 2+ | Longitudinal | Various | 29 |
SIGN: Scottish Intercollegiate Guidelines Network; NSBHR: nonspecific bronchial hyperresponsiveness; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SIC: specific inhalation challenge; VC: vital capacity; TDI: toluene diisocyanate; HMW: high molecular weight; LMW: low molecular weight; MDI: methylene diphenyl diisocyanate. +: relationship between worse lung function at baseline (FEV1, FVC, VC, NSBHR and SIC) and worse asthma status at follow-up; - : relationship between worse lung function at baseline (FEV1, FVC, VC, NSBHR and SIC) and better asthma status at follow-up.